Syndax Pharmaceuticals Inc stock is traded at $9.37, with a volume of 5,794,182. It is down -10.33% in the last 24 hours and down -47.45% over the past month. Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Previous Close:
$10.45
Open:
$10.38
24h Volume:
5,794,182
Relative Volume:
1.20
Market Cap:
$843.56M
Revenue:
$217.42M
Net Income/Loss:
-$243.25M
P/E Ratio:
-
EPS:
-$2.80
Net Cash Flow:
-$278.35M
1W Performance:
-33.78%
1M Performance:
-47.45%
6M Performance:
-53.38%
1Y Performance:
-37.95%
1-Day Range:
$9.29$10.49
1-Week Range:
$9.29$14.69
52-Week Range:
$9.29$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
781-419-1400Address
730 THIRD AVENUE, NEW YORK, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS